美沙拉嗪联合益生菌治疗炎症性肠病临床疗效观察

Clinical Observation of Mesalazine Combined with Probiotics in the Treatment of Inflammatory Bowel Disease

目的观察美沙拉嗪联合益生菌治疗炎症性肠病临床疗效。方法随机选取绵阳市肛肠病医院2016年5月—2018年7月进行诊治的炎症性肠病(IBD)患者98例,采用随机数字表法按1∶1的比例分为对照组和联合组,各49例。对所有IBD患者给与常规性抗炎治疗,对照组患者使用美沙拉嗪治疗,联合组在对照组的基础上使用益生菌治疗。对两组患者进行临床治疗效果评价、内镜检查疗效评价和不良反应评价。结果临床治疗效果总有效率对照组79.59%显著小于联合组93.88%(P<0.05),对所有患者进行内窥镜疗效总有效率对照组77.55%显著小于联合组91.84%(P<0.05),对照组不良反应率为32.65%显著高于联合组10.20%(P<0.05)。结论使用美沙拉嗪联合益生菌治疗炎症性肠病能够显著提升治疗效果,安全性高,不良反应率低,值得临床推广和应用。

Objective To observe the clinical efficacy of mesalazine combined with probiotics in the treatment of inflammatory bowel disease.Methods A total of 98 patients with IBD who underwent diagnosis and treatment from May 2016 to July 1818 in hospital were randomly selected.The random number table method was used to divide the patients into the control group and the combined group,49 cases in each group.All patients with IBD were given conventional resistance.For the treatment of inflammation,the control group was treated with mesalazine,and the combined group was treated with probiotics on the basis of the control group.The clinical treatment effect evaluation,endoscopic efficacy evaluation and adverse reaction evaluation were performed on the two groups of patients.Results The total effective rate of clinical treatment was 79.59%in the control group and 93.88%in the combined group(P<0.05).The total effective rate of endoscopic efficacy in all patients was 77.55%,which was significantly lower than that in the combined group(91.84%,P<0.05).The adverse reaction rate of the control group was 32.65%significantly higher than that of the combined group(10.20%)(P<0.05).Conclusion The use of mesalazine combined with probiotics for the treatment of inflammatory bowel disease can significantly improve the therapeutic effect,with high safety and low adverse reaction rate,which is worthy of clinical promotion and application.